Drug Trial Radar · NCT00509795
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Last checked: Nov 20, 2026Latest source record: Dec 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,217
Actual
Start
Aug 2007
Primary completion
Sep 2010
Study completion Jul 2011
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Aug 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
Conditions
- Macular Degeneration
Interventions
ranibizumabBiological
Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)Biological
Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)Biological
Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)Biological
Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)Time frame: Baseline and at week 52
Locations
188 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Beverly Hills, California
Site not named
Campbell, California
Site not named
Fullerton, California
Site not named
Glendale, California
Site not named
Irvine, California
Site not named
La Jolla, California
Site not named
Loma Linda, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Menlo Park, California
Site not named
Mountain View, California
Site not named
Oakland, California
Site not named
Palm Springs, California
Site not named
Pasadena, California
Site not named
Poway, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Santa Ana, California
Site not named
Torrance, California
Site not named
Ventura, California
Site not named
Westlake Village, California
Site not named
Yorba Linda, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Denver, Colorado
Site not named
Bridgeport, Connecticut
Site not named
Hamden, Connecticut
Site not named
New Haven, Connecticut
Site not named
New London, Connecticut
Site not named
Altamonte Springs, Florida
Site not named
Boynton Beach, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Myers, Florida
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.